Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07823790
PHASE2

ONO-4915 in Patients With Primary Sjogren's Disease

Sponsor: Ono Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

To evaluate the efficacy and safety of ONO-4915 in patients with primary Sjogren's disease

Official title: A Phase II Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Study in Patients With Primary Sjogren's Disease to Evaluate the Efficacy and Safety of Subcutaneously Administered ONO-4915

Key Details

Gender

All

Age Range

18 Years - 74 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-10

Completion Date

2029-02

Last Updated

2026-09-16

Healthy Volunteers

No

Interventions

DRUG

ONO-4915

Subcutaneous administration

DRUG

Placebo

Subcutaneous administration